Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Saronno – page 57

2 862 clinical trials in Saronno, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Saronno at a glance
2 862
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 862 trials in Saronno

Open in trial search

Ovarian cancer recurrent

Recruiting

Study Comparing Olaparib and Chemotherapy for Patients with Recurrent Ovarian Cancer After Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Bladder cancer

Recruiting

Study of EG-70 for Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to BCG or High-Risk Patients New to BCG or with Incomplete BCG Treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lauromacrogol 400
  • Sponsor:Engene Inc.

Non-small cell lung cancer

Recruiting

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dacomitinib
  • Sponsor:Fondazione Ricerca Traslazionale

Chronic myelomonocytic leukaemia

Recruiting

Study of Azacitidine, Venetoclax, and Tagraxofusp for Patients with Higher-Risk Chronic Myelomonocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tagraxofusp
  • Sponsor:GCP-Service International West GmbH

Chronic myeloid leukaemia

Recruiting

Study of Olverembatinib and Bosutinib for Patients with Chronic Phase Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Ascentage Pharma Group Inc.

Plasmablastic lymphoma

Recruiting

Study on the Effects and Safety of Daratumumab, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Plasmablastic Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Fondazione Italiana Linfomi Ets

Osteogenesis imperfecta

Recruiting

Study on Losartan and Hydrochlorothiazide for Osteogenesis Imperfecta in Patients Aged 16 and Above

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrochlorothiazide
  • Sponsor:Istituto Ortopedico Rizzoli

Pancreatic carcinoma

Recruiting

Study Comparing Gemcitabine and Paclitaxel with Drug Combination for Patients with Advanced Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.

Ovarian cancer recurrent

Recruiting

Study of Olaparib for Patients with Recurrent Ovarian Cancer Without BRCA Gene Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Anal incontinence

Recruiting

Study on ICEF15 for Treating Fecal Incontinence in Patients with Anal Sphincter Dysfunction

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ICEF15
  • Sponsor:Innovacell GmbH

Non-small cell lung cancer stage III

Recruiting

Study on Durvalumab and Chemotherapy for Patients with Relapsed Stage III Non-Small Cell Lung Cancer After Chemoradiotherapy and Durvalumab Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Fondazione Ricerca Traslazionale

Uveal melanoma+1

Recruiting

Study of Roginolisib for Patients with Advanced Uveal Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:iOnctura SA

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Saronno

What the registry says about research in the country

01 Respiratory Oncology

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, including studies evaluating novel therapeutic approaches for patients with specific genetic mutations.

  • MET deregulation therapy assessment
  • Second-line combination treatments
  • EGFR mutation targeting

Research emphasizes personalized treatment strategies for advanced and metastatic disease states.

02 Women's Oncology

Comprehensive studies addressing breast cancer and gynecological malignancies, with focus on treatment timing and maintenance therapies.

  • Endocrine-responsive breast cancer treatment
  • Ovarian cancer maintenance therapy
  • BRCA wild-type cancer management

Investigations aim to optimize treatment sequences and improve patient outcomes.

03 Specialized Oncology & Cardiology

Innovative research in renal cell carcinoma treatment and cardiac conditions, particularly focusing on novel therapeutic approaches.

  • Metastatic renal cancer therapy
  • Atrial fibrillation management
  • Targeted combination therapies

Studies evaluate both oncological interventions and cardiovascular treatments for high-risk patients.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.